{
  "trial_id": "NCT01482767",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Men and women 18 years of age or older",
      "label": "met"
    },
    {
      "criterion": "Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody for at least 180 days",
      "label": "met"
    },
    {
      "criterion": "Serum or plasma HCV RNA level 10,000 IU/mL or greater obtained within 42 days prior to study entry.",
      "label": "met"
    },
    {
      "criterion": "Screening HCV genotype 1 performed within 6 months prior to study entry",
      "label": "met"
    },
    {
      "criterion": "Liver biopsy or HCV FibroSURE\u2122 test within 104 weeks prior to study entry with interpretation consistent with chronic HCV infection",
      "label": "met"
    },
    {
      "criterion": "Alpha feto protein (AFP) levels less than 50",
      "label": "met"
    },
    {
      "criterion": "HIV-1 infection",
      "label": "met"
    },
    {
      "criterion": "Currently not on any antiretroviral therapy (ART) for at least 4 weeks immediately prior to entry or on stable ART for at least 8 weeks prior to study entry using a dual NRTI backbone PLUS one of the following: EFV, RAL, LPV/RTV 400/100 mg twice daily, ATV/RTV, DRV/RTV 600/100 mg twice daily",
      "label": "met"
    },
    {
      "criterion": "CD4+ T-cell count greater than 200 cells/mm^3 obtained within 42 days prior to study entry.",
      "label": "met"
    },
    {
      "criterion": "For participants on ART, screening plasma HIV-1 RNA less than 50 copies/mL obtained within 42 days prior to study entry. For participants not on ART, plasma HIV-1 RNA less than 50,000 copies/mL obtained within 42 days prior to study entry.",
      "label": "met"
    },
    {
      "criterion": "The following laboratory values within 42 days prior to entry: Absolute neutrophil count (ANC) 1000/mm^3 or greater",
      "label": "met"
    },
    {
      "criterion": "Hemoglobin greater than 12 g/dL for men and greater than 11 g/dL for women",
      "label": "met"
    },
    {
      "criterion": "Platelet count greater than 80,000 per mm^3",
      "label": "met"
    },
    {
      "criterion": "Creatinine less than 1.5 mg/dL",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.",
      "label": "unknown"
    },
    {
      "criterion": "Evidence of decompensated liver disease manifested by the presence of or history of ascites, variceal bleeding, or hepatic encephalopathy",
      "label": "not_met"
    },
    {
      "criterion": "Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency.",
      "label": "unknown"
    }
  ],
  "notes": "The patient has a history of inguinal hernia surgery and is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT01482767",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}